Physician profile
Martin E Edep
NPI 1245222355
$3,480.89
in general payments reported to CMS, 2019-2025
23 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $468 · 2021: $289 · 2022: $754 · 2023: $453 · 2024: $533 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,450.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $916.41 | 2019-2025 | Jot Dx, Aveir, Triclip |
| Philips North America LLC | $694.11 | 2020-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und |
| Amgen INC. | $391.79 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $286.34 | 2019-2025 | |
| Pfizer INC. | $209.19 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $148.06 | 2021-2023 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $137.29 | 2020-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $121.04 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $98.34 | 2021-2025 | General - Structural Heart, Watchman Flx |
| Biosense Webster, INC. | $70.60 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $48.95 | 2019-2022 | |
| Cleerly, INC. | $46.26 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Amarin Pharma, INC. | $46.26 | 2019-2021 | |
| Medtronic Vascular, INC. | $44.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.92 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $30.95 | 2024 | Impella |
| Cardiva Medical, INC. | $29.08 | 2022 | |
| Esperion Therapeutics, INC. | $27.44 | 2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.05 | 2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $20.92 | 2025 | Onpattro |
| Atricure, INC. | $20.52 | 2019 | |
| Cvrx, INC. | $20.06 | 2024 | Barostim Neo System |
| Akcea Therapeutics, INC. | $16.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Edep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.